Patents Assigned to Genentech
  • Anti-Ly6E antibodies and immunoconjugates and methods of use
    Patent number: 9724427
    Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: August 8, 2017
    Assignee: Genentech, Inc.
    Inventors: Chie Sakanaka, Peter Chang
  • Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
    Patent number: 9717730
    Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: August 1, 2017
    Assignee: GENENTECH, INC.
    Inventors: Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath, Jeffrey Wallin, Premal Patel
  • Anti-mesothelin antibodies and immunoconjugates
    Patent number: 9719996
    Abstract: The invention provides anti-mesothelin antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: August 1, 2017
    Assignee: GENENTECH, INC.
    Inventors: Mark Dennis, Suzanna J. Scales, Susan D. Spencer, Yin Zhang
  • COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF HEPATIC CANCERS
    Publication number: 20170210815
    Abstract: The present invention relates to methods of treating liver cancer using a Notch signaling inhibitor. Compositions and methods for the treatment of liver cancers are also provided.
    Type: Application
    Filed: December 8, 2016
    Publication date: July 27, 2017
    Applicant: Genentech, Inc.
    Inventors: Dorothy French, Erik Huntzicker, Christian W. Siebel
  • HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR
    Publication number: 20170210807
    Abstract: The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.
    Type: Application
    Filed: April 11, 2017
    Publication date: July 27, 2017
    Applicant: Genentech, Inc.
    Inventors: Sherman Fong, Mark Dennis
  • ALKYNYL ALCOHOLS AND METHODS OF USE
    Publication number: 20170210724
    Abstract: The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
    Type: Application
    Filed: April 7, 2017
    Publication date: July 27, 2017
    Applicant: Genentech, Inc.
    Inventors: Nicole Blaquiere, Georgette Castanedo, Jianwen A. Feng, Baihua Hu, Steven Staben, Po-wai Yuen, Guosheng Wu, Xingyu Lin, Jason Burch
  • BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
    Publication number: 20170210733
    Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation. Also described are methods of making the benzoxazepin oxazolidinone compounds having the Formula I structure.
    Type: Application
    Filed: April 7, 2017
    Publication date: July 27, 2017
    Applicant: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott
  • METHODS OF TREATING CANCER AND PREVENTING CANCER DRUG RESISTANCE
    Publication number: 20170209444
    Abstract: Provided herein are methods of using antagonists of G9a, for example, for treating cancer and/or preventing drug resistance in an individual. For example, a method of treating cancer in an individual comprising administering to the individual an antagonist of G9a alone or in combination with a cancer therapy agent is provided. In some embodiments, the antagonist of G9a increases the period of cancer sensitivity and/or delays development of cancer resistance.
    Type: Application
    Filed: June 23, 2015
    Publication date: July 27, 2017
    Applicant: Genentech Inc.
    Inventors: Marie Classon, Gulfem Dilek Guler, Robert Pitti, Jean-Philippe Stephan, Charles Albert Tindell
  • Production of proteins in glutamine-free cell culture media
    Patent number: 9714293
    Abstract: The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: July 25, 2017
    Assignee: GENENTECH, INC.
    Inventors: Martin Gawlitzek, Shun Luo, Christina Teresa Bevilacqua
  • METHODS OF TREATING AND PREVENTING CANCER DRUG RESISTANCE
    Publication number: 20170204187
    Abstract: Provided herein are combination therapies for the treatment of pathological conditions, such as cancer, using an antagonist of FGFR signaling and a B-raf antagonist.
    Type: Application
    Filed: June 12, 2015
    Publication date: July 20, 2017
    Applicant: Genentech, Inc.
    Inventors: Richard M. NEVE, Nicholas A. DOMPE, Timothy R. WILSON, Jeffrey SETTLEMAN
  • METHOD FOR PREPARING A COMPOSITION COMPRISING HIGHLY CONCENTRATED ANTIBODIES BY ULTRAFILTRATION
    Publication number: 20170204135
    Abstract: The present invention provides a method for preparing a composition comprising highly concentrated antibodies by ultrafiltration in batch concentration mode having a first constant feed rate step and a second controlled feed rate step.
    Type: Application
    Filed: March 17, 2017
    Publication date: July 20, 2017
    Applicants: Chugai Seiyaku Kabushiki Kaisha, Genentech, Inc.
    Inventors: Kelby LAU, Jean BENDER, Saeko TANAKA, Rumiko WAKAYAMA, Hidenari YAMADA, Tomonori ISODA, Masayoshi OH-EDA
  • Hedgehog antagonists having zinc binding moieties
    Patent number: 9708299
    Abstract: The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The compounds can be used in methods of treating proliferative diseases and disorders such as cancer.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: July 18, 2017
    Assignees: Genentech, Inc., Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Serine/threonine kinase inhibitors
    Patent number: 9708290
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: July 18, 2017
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: James F. Blake, Mark Joseph Chicarelli, Rustam Ferdinand Garrey, John Gaudino, Jonas Grina, David A. Moreno, Peter J. Mohr, Li Ren, Jacob Schwarz, Huifen Chen, Kirk Robarge, Aihe Zhou
  • Anti-transferrin receptor antibodies and methods of use
    Patent number: 9708406
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: July 18, 2017
    Assignee: GENENTECH, INC.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S. Dennis, James A. Ernst, Ryan J. Watts, Gregory A. Lazar
  • ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20170197915
    Abstract: Described herein are compounds that are estrogen receptor modulators of Formula (I): and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein SERMF is a selective estrogen receptor modulator fragment and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: December 17, 2015
    Publication date: July 13, 2017
    Applicant: Genentech, Inc.
    Inventors: Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Steven P. Govek, Mehmet Kahraman, Johnny Y. Nagasawa, Nicholas D. Smith, Simon Charles Goodacre, Nicholas Charles Ray
  • USE OF CBP/EP300 AND BET INHIBITORS FOR TREATMENT OF CANCER
    Publication number: 20170196878
    Abstract: The present invention relates to the use of CBP/EP300 inhibitors and BET inhibitors for the treatment of cancer. In some embodiments, the use is to treat cancer that is resistant to BET inhibitors.
    Type: Application
    Filed: March 20, 2017
    Publication date: July 13, 2017
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Richard C. Centore, Andrew R. Conery, Karen Gascoigne, Robert J. Sims, III
  • METHODS OF TREATING ALZHEIMER'S DISEASE
    Publication number: 20170198030
    Abstract: Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided. Also provided are methods of selecting or identifying patients for treatment with an anti-Abeta antibody. Methods include the use of prognostic and/or predictive biomarkers.
    Type: Application
    Filed: August 17, 2016
    Publication date: July 13, 2017
    Applicant: Genentech, Inc.
    Inventor: Robert Graham
  • THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20170190662
    Abstract: The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: July 7, 2015
    Publication date: July 6, 2017
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe ANDREZ, Philippe BERGERON, Paul Robert BICHLER, Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Thilo FOCKEN, Wei GONG, Michael Edward GRIMWOOD, Abid HASAN, Ivan William HEMEON, Qi JIA, Brian SAFINA, Shaoyi SUN, Michael Scott WILSON, Alla Yurevna ZENOVA
  • Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
    Patent number: 9695240
    Abstract: The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: July 4, 2017
    Assignees: Genentech, Inc., Nerviano Medical Sciences S.R.L.
    Inventors: Italo Beria, Michele Caruso, John A. Flygare, Vittoria Lupi, Rita Perego, Paul Polakis, Andrew Polson, Matteo Salsa, Susan D. Spencer, Barbara Valsasina, Robert L. Cohen
  • Substituted benzamides and methods of use thereof
    Patent number: 9694002
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: July 4, 2017
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe Andrez, Paul Robert Bichler, Chien-An Chen, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Zhiguo Liu, Daniel F. Ortwine, Brian Safina, Daniel Sutherlin, Tao Sheng, Shaoyi Sun, Andrew D. White, Michael Scott Wilson, Alla Yurevna Zenova, Jiuxiang Zhu